Hunter C. Smith - 07 Jun 2022 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (SYRE)

Role
Director
Signature
/s/ James Kastenmayer, by power of attorney
Issuer symbol
SYRE
Transactions as of
07 Jun 2022
Net transactions value
$0
Form type
4
Filing time
09 Jun 2022, 21:19:53 UTC
Previous filing
15 Feb 2022
Next filing
06 Jul 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGLE Director Stock Option (right to buy) Award $0 +43,000 $0.000000 43,000 07 Jun 2022 Common Stock 43,000 $0.7300 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2022, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.

Remarks:

Exhibit 24 - Power of Attorney